- Home
- DMAC vs RIV Comparison
DMAC vs RIV Comparison
Compare DMAC & RIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- RIV
- Stock Information
- Founded
- DMAC 2000
- RIV 2015
- Country
- DMAC United States
- RIV United States
- Employees
- DMAC N/A
- RIV N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- RIV Finance Companies
- Sector
- DMAC Health Care
- RIV Finance
- Exchange
- DMAC Nasdaq
- RIV Nasdaq
- Market Cap
- DMAC 310.1M
- RIV 260.6M
- IPO Year
- DMAC N/A
- RIV N/A
- Fundamental
- Price
- DMAC $6.96
- RIV $11.98
- Analyst Decision
- DMAC Strong Buy
- RIV
- Analyst Count
- DMAC 3
- RIV 0
- Target Price
- DMAC $12.33
- RIV N/A
- AVG Volume (30 Days)
- DMAC 343.5K
- RIV 87.6K
- Earning Date
- DMAC 11-12-2025
- RIV 01-01-0001
- Dividend Yield
- DMAC N/A
- RIV 12.85%
- EPS Growth
- DMAC N/A
- RIV N/A
- EPS
- DMAC N/A
- RIV N/A
- Revenue
- DMAC N/A
- RIV N/A
- Revenue This Year
- DMAC N/A
- RIV N/A
- Revenue Next Year
- DMAC N/A
- RIV N/A
- P/E Ratio
- DMAC N/A
- RIV N/A
- Revenue Growth
- DMAC N/A
- RIV N/A
- 52 Week Low
- DMAC $3.19
- RIV $9.63
- 52 Week High
- DMAC $7.49
- RIV $12.43
- Technical
- Relative Strength Index (RSI)
- DMAC 58.60
- RIV 39.53
- Support Level
- DMAC $6.75
- RIV $11.91
- Resistance Level
- DMAC $7.13
- RIV $12.03
- Average True Range (ATR)
- DMAC 0.28
- RIV 0.07
- MACD
- DMAC -0.06
- RIV 0.00
- Stochastic Oscillator
- DMAC 50.00
- RIV 49.75
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.